This report on the pharmaceutical industry will be published in two parts. Part I begins with a summary of the study and its conclusions. The authors then provide an overview of the characteristics of the industry and current trends in its growth and structure: production and consumption, employment, research and development, capital investment, firm and product concentration and product competition, and pricing. A discussion of international trade follows, covering intra- and inter-regional, intra-firm, and intra-industry trade. The report will continue in the next issue of the Journal (Part II) with a look at foreign direct investment, inter-firm networks, and governmental policies.
Get full access to this article
View all access options for this article.
References
1.
OECD. The Pharmaceutical Industry: Trade Related Issues. Paris, 1985.
2.
Commission of the European Communities.Panorama of EU Industry 94. Brussels, 1995.
3.
SCRIP.Pharmaceutical Company League Tables. PJB Publications, Surrey, England, 1981, 1982, 1990, 1991, 1992, 1993 [and other SCRIP publications].
4.
BallanceR.PoganyJ., and ForstnerH.The World's Pharmaceutical Industries. UNIDO, Edward Elgar, Aldershot, 1992.
5.
OECD.Health Care Data File. Paris, 1994.
6.
RaugelP.-J.European Biotechnology Investments in North America and Japan. BFE 9, November/December 1992.
7.
DaltonD. H., and SerapioM. G.U.S. Research Facilities of Foreign Companies. U.S. Department of Commerce, 1992.
8.
U.S. Department of Commerce.Foreign Direct Investment in the United States: An Update. Washington, D.C., 1993.
9.
U.S. Congress, Office of Technology Assessment. Multinationals and the U.S. Technology Base. U.S. Government Printing Office, Washington, D.C., 1994.
10.
Financial Times, May 9, 1994 [quoting Ernst and Young].
11.
De WolfP. In L'Europe et la globalisation: Acquisitions et accords dans l'industrie, edited by SachwaldF.. Masson, Paris, 1993.
12.
OECD.Intra-firm Trade. Paris, 1993.
13.
GrubelH. G., and LloydP. J.Intra-industry Trade: The Theory and Measurement of International Trade in Differentiated Products. MacMillan, London, 1975.
14.
TarabusiCasadio C.Globalisation in the pharmaceutical industry: Technological change and competition in a triad perspective. STI Rev.13. OECD, Paris, 1993.
15.
Chemical industryR&D spending to rise modestly. Chem. Eng. News, January 25, 1993.
16.
Commission of the European Communities.Panorama of EC Industries 1991–92. Brussels, 1993.
17.
Commission of the European Communities.Panorama of EC Industries 93. Brussels, 1994.
18.
Commission of the European Communities.Report on Competition Policy, various issues.
19.
EAG.Generic Pharmaceuticals: The Threat. London1989.
20.
Japanese chemical companies still mired in slump.Chem. Eng. News, February 8, 1993.
21.
OECD.Competition Policy in OECD Countries. Paris, various issues.
22.
OECD.Globalisation of Industrial Activities: Four Case Studies. Paris, 1992.
23.
OECD.The International Sourcing of Manufactured Intermediate Inputs: By Canada, France, Germany, Japan, the United Kingdom and the United States. Paris, 1992.
24.
SchreyerP.Competition policy and industrial adjustment. STI Rev.10. OECD, Paris, 1992.
25.
U.S. Department of Commerce.Foreign Direct Investment in the United States. Washington, D.C., 1991.
26.
U.S. Department of Commerce.U.S. Industrial Outlook 1992, 1993 and 1994. Washington, D.C., various years.
27.
U.S. International Trade Commission.Global Competitiveness of U.S. Advanced-Technology Manufacturing Industries: Pharmaceuticals. U.S.ITC Publication 2437. Washington, D.C., September 1991.
28.
VickeryG.A survey of international technology licensing. STI Rev.4. OECD, Paris, 1988.
